Colorectal Cancer Clinical Trial
Official title:
A Randomised Phase III Trial Comparing Hepatic Arterial Injection of Yttrium-90 Resin Microspheres (SIR-spheres) Plus Systemic Maintenance Therapy Versus Systemic Maintenance Therapy Alone for Patients With Unresectable Liver Metastases From Colorectal Cancer Which Are Controlled After Induction Systemic Therapy
The investigators propose to conduct a randomised phase III trial evaluating a maintenance strategy comparing hepatic arterial injection of Yttrium-90 resin microspheres plus continuing simplified chemotherapy with/without targeted therapy versus continuing simplified chemotherapy with/without targeted therapy alone for patient with dominant or exclusive and unresectable liver mCRC controlled after 3-6 months of chemotherapy induction.
Status | Recruiting |
Enrollment | 162 |
Est. completion date | December 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
Inclusion criteria: 1. Willing and able to provide written informed consent 2. Histologically confirmed adenocarcinoma of the colon or rectum, with or without primary tumour in situ. Unequivocal and measurable (RECIST 1.1) CT evidence of liver metastases which are not treatable by surgical resection and/or local ablation with curative intent at the time of trial entry. 3. Partial response or stable disease (RECIST 1.1 criteria, controlled metastatic disease) after chemotherapy induction with oxaliplatin and/or irinotecan based induction chemotherapy (doublet or triplet combinations) +/- targeted therapies during 3 to 6 months. 4. Trial inclusion must be performed between 3 and 6 months since the date of the first course of chemotherapy (induction) administration. 5. Limited extra-hepatic metastases in the lung and/or lymph nodes are permitted. Metastases in the lung must either be not more than five nodules in number with no individual nodule more than 1 cm in diameter or 1 single lesion of up to 1.7 cm in diameter. Involvement of lymph nodes in 1 single anatomic region (pelvis, abdomen or chest) are permitted provided their longest diameter measures less than 2 cm. 6. All imaging evidence used as part of the screening process must be within 28 days prior to the time of randomisation. 7. Suitable for either treatment regimen as determined by clinical assessment undertaken by the Investigator. 8. Patients may have received adjuvant chemotherapy or (neo-) adjuvant chemo-radiotherapy to the pelvis, provided the last dose of chemotherapy was administered at least 6 months prior to begin chemotherapy induction. Previous radiotherapy to the pelvis is not an exclusion criterion. 9. WHO performance status 0 - 1 10. Adequate hematological, renal and hepatic function as follows: Hematological Neutrophils > 1.5 x 109/L Platelets > 100 x 109/L Renal Creatinine < 1.5 x ULN (Upper Limit Normal) Hepatic Bilirubin = 1.0 X ULN Albumin = 30g/L ALT = 5.0 x ULN AST = 5.0 x ULN LDH = 2.5 x ULN The date of blood tests must be within 28 days prior to the time of randomisation. 11. Age 18 years or older. 12. Female patients must either be postmenopausal, sterile (surgically or radiation- or chemically-induced), or if sexually active using an acceptable method of contraception. 13. Male patients must be surgically sterile or if sexually active and having a pre-menopausal partner must be using an acceptable method of contraception. 14. Life expectancy of at least 3 months without any active treatment. Exclusion criteria 1. Evidence of ascites, cirrhosis, portal hypertension, main portal venous tumour involvement or thrombosis as determined by clinical or radiological assessment. 2. More than 6 months since last chemotherapy administration before trial inclusion. 3. Previous radiotherapy delivered to the upper abdomen. 4. Non-malignant disease that would render the patient unsuitable for treatment according to this protocol. 5. Prior major liver resection: remnant liver < 50% of the initial liver volume. Patient with a biliary stent can be included. 6. Liver tumor involvement > 80% before study inclusion (not at diagnosis but when trial inclusion for the patient is planned). 7. Resectable metastatic disease at trial inclusion. 8. Progressive disease during first-line metastatic chemotherapy. Adjuvant chemotherapy for colorectal cancer is not an exclusion criterion provided that it was completed more than 6 months prior to start of 1st line chemotherapy. 9. No oxaliplatin or irinotecan use during the first 3 to 6 months induction chemotherapy. 10. Pregnant or breast feeding. 11. Concurrent or prior history of cancer other than adequately treated non melanoma skin cancer or carcinoma in situ of the cervix. 12. Severe allergy to non-ionic contrast agents which would prevent contrast media use during the study. |
Country | Name | City | State |
---|---|---|---|
Belgium | ASZ Aalst | Aalst | |
Belgium | CUB Hôpital Erasme | Brussels | |
Belgium | Institut Jules Bordet | Brussels | |
Belgium | University of St-Luc | Brussels | |
Belgium | Grand Hôpital de Charleroi | Charleroi | |
Belgium | University of Antwerp | Edegem | Antwerp |
Belgium | ZOL Genk | Genk | |
Belgium | AZ St-Lucas Gent | Gent | |
Belgium | AZ Groeninge | Kortrijk | |
Belgium | CHU de Liège | Liège |
Lead Sponsor | Collaborator |
---|---|
Universiteit Antwerpen |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | SIR-spheres treatment | Prediction and evaluation of SIRspheres treatment response (only for Belgian sites) | Up to 42 months | |
Primary | Time to progression (TTP1 overall) | Time to first progression (TTP1 overall) | Up to 36 months | |
Secondary | Time to global progression (TTP1 + TTP2) | - Time to global progression (TTP1 + TTP2), Time to second progression (TTP2), TTP1 liver only | Up to 42 months | |
Secondary | PFS | Progression free survival | Up to 42 months | |
Secondary | Safety | Up to 42 months | ||
Secondary | R0 resection rate | Up to 42 months | ||
Secondary | Quality of life | Using EORTC QLQ C30 EQ-5D |
Up to 42 months | |
Secondary | Overall Survival (OS) | Up to 42 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Not yet recruiting |
NCT05775146 -
SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases
|
Phase 2 | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 |